Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SER
Strong SellHot AirSerina Therapeutics, Inc. · Healthcare · United States · $62M · Avg Vol: $162K/d
14
StockRankGet insider-trade alerts
Q
15
V
27
M
51
P/E (TTM)
—
ROE
-207.9%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.5M | 3.0M | 0 | 0 | 500.0% | — | — | — | — |
| EPS | -0.41 | 0.21 | -0.56 | -0.81 | — | -1.87 | -1.41 | -1.05 | — |
| Shares | 25.4M | 25.4M | 25.4M | 25.4M | 0.0% | 25.4M | — | — | — |
| Debt | 1.8M | 3.4M | 0.3M | 3.1M | 20.2% | 3.8M | — | — | — |
| Equity | -37.8M | -32.3M | 0.6M | -37.0K | — | — | — | — | — |
| Op CF | -2.1M | -2.5M | -17.1M | -18.0M | — | -21.1M | — | — | — |
| Inv CF | 1.0M | -0.5M | -22.0K | -59.0K | — | — | — | — | — |
| Fin CF | 1.3M | 10.1M | 13.2M | 17.4M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+22.5%
SMA 50SMA 200
Close
$2.50
RSI (14)
45.0
52W High
$5.83
From 52W High
0.4%
SCORE BREAKDOWN
Quality
15
ROIC
-615.8%0.8
ROE
-207.9%4.2
GP/Assets
-202.4%0.1
Op. Margin
0.0%38.1
FCF/Assets
-259.2%0.5
Piotroski
29.5
Int. Cover
-50.0x5.9
D/E Ratio
0.20x49.9
Current Ratio
6.65x79.8
Value
27
P/E (TTM)
—N/A
EV/EBITDA
-2.0x25.0
P/FCF
—N/A
P/B
3.7x38.5
P/S
—N/A
Div Yield
—N/A
Momentum
51
52W High %
43%16.8
RS 6M
54%92.3
SMA 50/200
1.04x65.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+44%51.0
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$62M
P/E (Forward)
-2.6x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SER are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SER | Serina Therapeutics, Inc.(you) | $62M | 14 | Strong Sell |
| HYFT | MindWalk Holdings Corp. | $65M | 14 | Strong Sell |
| IMA | ImageneBio, Inc. | $61M | 15 | Strong Sell |
| INKT | MiNK Therapeutics, Inc. | $58M | 15 | Strong Sell |
| PLRX | Pliant Therapeutics, Inc. | $69M | 12 | Strong Sell |
| ELOX | Eloxx Pharmaceuticals, Inc. | $52M | 15 | Strong Sell |
| OSTX | OS Therapies Incorporated | $76M | 15 | Strong Sell |
| TELO | Telomir Pharmaceuticals, Inc. | $78M | 13 | Strong Sell |
| ANVS | Annovis Bio, Inc. | $73M | 12 | Strong Sell |
| HYPD | Hyperion DeFi, Inc. | $51M | 16 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%